Form 8-K Celldex Therapeutics, For: Apr 16

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Form 8-K Celldex Therapeutics, For: Apr 16

Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform

April 16, 2018 1:02 PM EDT

Cowen downgraded Celldex Therapeutics (NASDAQ: CLDX) from Outperform to Market Perform.

Analyst Boris Peaker commented, "CLDX announced this morning that glemb'a pivotal METRIC study in gpNMB+ TNBC failed to meet its primary PFS endpoint. All glembatumumab development, including checkpoint inhibitor combination in melanoma, will... More

Celldex Therapeutics (CLDX) PT Lowered to $2.50 at H.C. Wainwright

April 16, 2018 10:54 AM EDT

H.C. Wainwright lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $2.50 (from $10.00) while maintaining a Buy rating.

Analyst Joseph Pantginis commented, "This morning, Celldex announced that the Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic... More

Celldex (CLDX) Set to Open Lower By 49% After METRIC Study Fails

April 16, 2018 8:24 AM EDT

Celldex (NASDAQ: CLDX) was set to open lower by 49% Monday morning after announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.

... More